MENU

3 S&P/ASX 200 stocks the “buy on a low” mentality doesn’t apply to

Buy on a low, sell on a high.

It’s the mantra of the successful stock investor.

But is there ever any exception to the rule?

We’ve picked 3 stocks that seem to be defying this age-old adage.

Here’s why.

CSL Limited (ASX: CSL)

The overwhelming consensus on $85.9 billion market cap biopharmaceutical company CSL Limited is – it’s not too late.

Sure, the CSL share price might have zoomed up 38% in the last 12 months, but the company has continued to assert itself as one of the ASX’s most quality businesses in that time, with the growth of its Seqirus influenza business, gains in its core plasma unit and an impressive pipeline of pharmaceutical products almost assured to see the company continue to book gains for the foreseeable future.

CSL recently increased its expectations of its full-year profit to record levels – with NPAT expected to be in the range of US$1.6 billion to $1.7 billion up between 26% and 28% due to vaccine sales boosted by a severe flu season and bumper sales of its haemophilia products.

Investors are hard-pressed to name a growth stock more impressive than CSL right now, and its clean balance sheet and competitive advantage sure doesn’t hurt either.

If you’ve already got them, hold onto them, if you want them, it’s probably not too late.

Cochlear Limited (ASX: COH)

Healthcare is a burgeoning sector, with the ageing population driving its growth.

Implantable device company Cochlear Limited has a stronghold on its market across Australia, the Asia Pacific, Europe, the Middle East and Africa, to name a few, with more than 20 countries now distributing its products.

There’s plenty of proof this market-leader’s operations will continue to expand – with global demand for its products continually on the up and its lack of viable competitors clearly evident also.

But with the Cochlear share price currently sitting at $198.89 – up from $159.99 at this time last year – is the stock “too expensive” for a current buy-in?

Consensus is that buy and hold opportunities for Cochlear are still relevant, with NPAT for its FY18 expected to be between $240 million and $250 million which would be a rise of between 7% and 12% on FY17.

The market has high expectations on Cochlear, but the company seems to continue to deliver the goods and there’s little evidence that it will deviate from this trajectory going forward.

Macquarie Group Ltd (ASX: MQG)

The big banks are under fire at the moment as the Royal Commission rages on, but Macquarie Group Ltd has always done things a little differently, and the global financial services company has often been referred to as the only banking share you should actually bank on – for this reason.

To start with, Macquarie has a fairly firm focus on infrastructure, with a 10-year dividend growth rate of 12.5% alongside interests in emerging sectors like renewable energy – which could book significant returns in the future.

Macquarie has a history of cashing in on global trends and keeps its own fundamentals tidy with its share price pushing higher in the last week off the back of gains out of the US banking sector.

The $38.4 billion market cap company has certainly done plenty right so far, and it’s showing no signs of a slowdown despite the volatility of the overall climate in its sector.

We expect the big winners to yield big dividends, right?

Find out our #1 dividend pick to grow your wealth over the new financial year for FREE here!

Financial year 2018 is here and The Motley Fool's dividend detective Andrew Page has revealed his must buy dividend share to grow your wealth in 2018.

You might not know this market leader's name, but it's rapidly expanding into a highly profitable niche market here in Australia. Even better, the shares boast a strong, fully franked dividend that should balloon in the years to come. In other words, we're looking at the holy grail of incredible long-term growth potential AND income you can watch accruing in your account in real time!

Simply click here to grab your FREE copy of this up-to-the-minute research report on our #1 dividend share recommendation now.

Motley Fool contributor Carin Pickworth has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.